0001104659-22-129900.txt : 20221223 0001104659-22-129900.hdr.sgml : 20221223 20221223161525 ACCESSION NUMBER: 0001104659-22-129900 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20221220 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221223 DATE AS OF CHANGE: 20221223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Theriva Biologics, Inc. CENTRAL INDEX KEY: 0000894158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133808303 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12584 FILM NUMBER: 221485546 BUSINESS ADDRESS: STREET 1: 9605 MEDICAL CENTER DRIVE STREET 2: SUITE 270 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: (734) 332-7800 MAIL ADDRESS: STREET 1: 9605 MEDICAL CENTER DRIVE STREET 2: SUITE 270 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: Synthetic Biologics, Inc. DATE OF NAME CHANGE: 20120305 FORMER COMPANY: FORMER CONFORMED NAME: ADEONA PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20081027 FORMER COMPANY: FORMER CONFORMED NAME: PIPEX PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20061214 8-K 1 tm2233416d1_8k.htm FORM 8-K
0000894158 false 0000894158 2022-12-20 2022-12-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 20, 2022

 

THERIVA BIOLOGICS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-12584   13-3808303

(State or other jurisdiction of

incorporation)

   (Commission File No.)  

(IRS Employer Identification

No.)

 

9605 Medical Center Drive, Suite 270

Rockville, Maryland 20850

(Address of principal executive offices and zip code)

 

(301) 417-4364

Registrant’s telephone number, including area code

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Common stock, par value $0.001 per share TOVX NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 1.01. Entry into a Material Definitive Agreement

 

On December 22, 2022, Theriva Biologics, Inc. (the “Company”) repurchased an aggregate of 720,000 shares of its common stock, par value $0.0001 (the “Common Stock”) from Manel Maria Cascallo Piqueras, Ramon Alemany and Gabriel Maria Capella Minar (the “Selling Stockholders”), three founders of its subsidiary Theriva Biosciences S.L. (formerly known as VCN Biosciences S.L.) in a privately negotiated transaction pursuant to the terms of a Share Repurchase Agreement entered into a Share Repurchase Agreement (the “Share Repurchase Agreement”) entered into on December 20, 2022 with each of the Selling Stockholders. The price per share was $0.4001, which was the closing price of the Common Stock on the day prior to the closing for an aggregate purchase price was $288,072. The closing was subject to fulfillment of certain conditions, including delivery of certain closing documents. The Share Repurchase Agreement contains customary representations, warranties and covenants of the parties. The repurchase was funded from the Company’s cash on hand and the shares to be repurchased will be held as treasury stock by the Company. The Selling Stockholders acquired the shares of the Company’s Common Stock as consideration for the sale of their shares of the subsidiary to the Company in March 2022.

 

The foregoing description of the Shares Repurchase Agreement is a summary and is qualified in its entirety by the terms of the Share Repurchase Agreement, a copy of which is attached to this Current Report on Form 8-K as Exhibit 10.1 and is incorporated herein by reference .

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
Number		   Description
     
10.1   Form of Share Repurchase Agreement between Theriva Biologics, Inc. and certain selling stockholders
     
104   Cover Page Interactive Data File (embedded within the XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: December 23, 2022 THERIVA BIOLOGICS, INC.
       
  By: /s/ Steven A. Shallcross
    Name: Steven A. Shallcross
    Title: Chief Executive Officer and Chief Financial Officer

 

 

 

 EX-10.1 2 tm2233416d1_ex10-1.htm EXHIBIT 10.1

Exhibit 10.1 

 

SHARE REPURCHASE AGREEMENT

 

This Share Repurchase Agreement is entered into effective as of December 20, 2022, by and among Theriva Biologics, Inc. located at 9605 Medical Center Drive, Suite 270, Rockville, Maryland 20850 (the “Corporation”) and [_____________________] with an address at _________________________ (the “Selling Stockholder”).

 

WHEREAS, Selling Stockholder desires to sell to the Corporation Two Hundred Forty Thousand (240,000) shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Corporation and the Corporation is willing to repurchase the Shares from the Selling Stockholder for the Aggregate Purchase Price (as defined below) upon the terms and subject to the conditions set forth in this Agreement.

 

NOW, THEREFORE, in consideration of the premises and the representations, warranties, covenants and undertakings contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

ARTICLE I

 

REPURCHASE AND PAYMENT

 

1.1            Repurchase and Sale of Shares. Upon the terms and subject to the conditions set forth in this Agreement and in reliance on the representations, warranties and agreements set forth in this Agreement, at the Closing (defined below), (i) the Selling Stockholder shall sell, transfer and deliver the Shares to the Company, free and clear of all mortgages, liens, pledges, claims, charges, security interests, adverse claims, transfer restrictions or encumbrances of any kind (“Liens”) and (ii) the Corporation shall purchase and acquire the Shares from the Selling Stockholder, in each case in exchange for the payment by the Company, pursuant to paragraph (b) below, of an amount equal to the product of the Purchase Price and Two Hundred and Forty Thousand (240,000) which is the number of Shares being sold by the Selling Stockholder hereunder (the product, the “Aggregate Purchase Price”) to such Selling Stockholder on the Closing Date (defined below).  The Selling Stockholder hereby acknowledges and agrees that receipt of the Aggregate Purchase Price shall constitute complete satisfaction of all obligations or any other sums due to such Selling Stockholder with respect to repurchase of the Shares.

 

1.2            Payment for Shares. The purchase price (the “Purchase Price”) for each share of Common Stock sold by the Selling Stockholder shall be the closing price of the Common Stock on the day prior to the Closing (as such term is defined below) . Effective upon his receipt of the Aggregate Purchase Price, the Stockholder hereby irrevocably appoints any officer, employee, or agent of the Corporation as his attorney to cancel or transfer the Shares on the books of the Corporation with the full power of substitution.

 

1.3            Closing. The closing of the transaction contemplated hereby (the “Closing”) shall take place at such place and on such date and time as may be mutually agreed to by the Selling Stockholder and the Corporation after satisfaction or waiver of all conditions set forth below (the “Closing Date”).  At the Closing:

 

(i)             The Corporation shall deliver to the Selling Stockholder the Aggregate Purchase Price by wire transfer of immediately available federal funds to an account designated by such Selling Stockholder.

 

(ii)            The Selling Stockholder shall (i) deliver to the Corporation an executed receipt for the Aggregate Purchase Price; (ii) cause the Shares to be transferred to the Company’s account at the transfer agent for the Corporation; and (iii) furnish any other documents reasonably requested by the Company’s transfer agent in order to effect the transaction contemplated hereby. From and after the Closing, the Selling Stockholder shall have no further right or title to or interest in the Shares or any dividends, distributions, equity interests or other rights in respect thereof.

 

 

 

 

ARTICLE II

 

REPRESENTATIONS AND WARRANTIES

 

Representations and Warranties of the Selling Stockholder

 

The Selling Stockholder represents and warrants to the Corporation as follows:

 

2.1            Power and Authority. The Selling Stockholder has the power and authority to execute and deliver this Agreement and consummate the transactions contemplated hereby.

 

2.2            Validity and Enforceability. This Agreement and all other instruments or documents executed by the Selling Stockholder in connection herewith have been duly executed by the Selling Stockholder, and constitute legal, valid, and binding obligations of the Selling Stockholder, enforceable in accordance with their respective terms.

 

2.3            No Encumbrances. The Selling Stockholder is the owner of the record of all right, title, and interest (legal and beneficial), free and clear of all liens, in and to the Shares. Upon the Closing, the Corporation will acquire good, valid and marketable title to such Shares, free and clear of all liens, encumbrances, equities, claims, liabilities, or obligations, whether absolute, accrued, contingent or otherwise, will be transferred to the Corporation.

 

2.4            Sophistication of Selling Stockholder. The Selling Stockholder (either alone or together with its advisors) has such knowledge and experience in financial or business matters that he is capable of evaluating the merits and risks of the transaction contemplated by this Agreement. The Selling Stockholder has had the opportunity to ask questions and receive answers concerning the terms and conditions of such transaction as he has requested. The Selling Stockholder has received all information that he believes is necessary or appropriate in connection with the transaction contemplated by this Agreement. The Selling Stockholder acknowledges that he has not relied upon any express or implied representations or warranties of any nature made by or on behalf of the Corporation, whether or not any such representations, warranties or statements were made in writing or orally, except as expressly set forth for the benefit of the Selling Stockholder in this Agreement.

 

2.5            Litigation. There is no action, suit, proceeding, claim, arbitration, litigation or investigation, at law or in equity (collectively, an “Action”), pending or, to the knowledge of such Selling Stockholder, threatened in writing against such Selling Stockholder which, if adversely determined, would prevent the consummation of the transaction contemplated by this Agreement. There is no Action by the Selling Stockholder pending or threatened against any other person relating to the Shares owned by such Selling Stockholder.

 

2.6            No Conflicts. Neither the execution, delivery or performance by the Selling Stockholder of this Agreement, nor the consummation of the transaction contemplated hereby by such Selling Stockholder will conflict with, result in the breach of, constitute a default under or accelerate the performance required by the terms of: (i) any judgment, order writ, decree, permit or license of any court or government, governmental or regulatory agency to which such Selling Stockholder or his assets may be subject; (ii) any statute, law, ordinance, regulation, rule, code, order, constitution, treaty, common law, judgment, writ, decree, permit, license or other requirement or rule; (iii) any other contract, agreement, commitment or instrument to which such Selling Stockholder is a party or by which any of his assets are bound; or (iv) constitute an event which, with or without due notice, the passage of time or action by a third party, would result in any of the foregoing.

 

2 

 

 

ARTICLE III

 

REPRESENTATIONS AND WARRANTIES OF THE CORPORATION

 

The Corporation represents and warrants to the Stockholder as follows:

 

3.1            Power and Authority. The Corporation has the power and authority to execute and deliver this Agreement and consummate the transactions contemplated hereby.

 

3.2            Organization and Qualification. The Corporation is incorporated, duly organized, validly existing and in good standing under the laws of the State of Nevada.

 

3.3            Validity and Enforceability. This Agreement and all other instruments or documents executed by the Corporation in connection herewith have been duly executed by the Corporation, and constitute legal, valid, and binding obligations of the Corporation, enforceable in accordance with their respective terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors’ rights generally and general principles of equity (whether considered in an action at law or in equity). The terms of this Agreement and the underlying transaction comply with all applicable laws of the United States of America and of any applicable state thereof and no consent, approval, order or authorization of, or registration, qualifications, designation, declaration or filing with, any federal, state or local governmental authority on the part of the Corporation is required in connection with the consummation of the repurchase of shares contemplated by this Agreement.

 

ARTICLE IV

 

CONDITIONS TO CLOSING

 

4.1            The obligations of the Corporation to consummate the transaction contemplated by this Agreement at the Closing are subject to each of the following conditions:

 

(i)              Representations and Warranties. The representations and warranties of the Selling Stockholder contained in this Agreement shall be true and accurate as of the Closing Date.

 

(ii)             Covenants and Agreements. Selling Stockholder must have performed and complied with all covenants, agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by the Selling Stockholder on or before the Closing.

 

(iii)            Legal Proceedings. No order of any nature issued by a court of competent jurisdiction restraining, prohibiting or affecting the consummation of the transaction contemplated by this Agreement (a “Court Order”) shall be in effect, and no claim, suit, action, investigation, inquiry or other proceedings by any Governmental Authority or other person (a “Governmental Proceeding”) shall be pending or threatened which questions the validity or legality of the transaction contemplated by this Agreement or prohibits the consummation of the Closing.

 

3 

 

 

4.2            Conditions to Obligation of the Selling Stockholder. The obligations of the Selling Stockholder to consummate the transaction contemplated by this Agreement at the Closing are subject to each of the following conditions:

 

(i)              Representations and Warranties. The representations and warranties of the Corporation contained in this Agreement shall be true and accurate as of the Closing Date.

 

(ii)             Covenants and Agreements. The Corporation must have performed and complied with all covenants, agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by the Corporation on or before the Closing.

 

(iii)            Legal Proceedings. No Court Order shall be in effect, and no Governmental Proceeding shall be pending or threatened which questions the validity or legality of the transaction contemplated by this Agreement or prohibits the consummation of the Closing.

 

ARTICLE V

 

MISCELLANEOUS

 

5.1            Notices. Any notice or communication required or permitted under this Agreement shall be sufficiently given if delivered in person or by certified mail, return receipt requested, to the addresses listed above, or to such other address as one party may have furnished to the other in writing. The notice shall be deemed received when delivered or signed for, or on the third day after mailing if not signed for.

 

5.2            Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective permitted successors and assigns.

 

5.3            Entire Agreement. This Agreement contains the entire agreement of the parties regarding the subject matter of this Agreement, and there are no other promises or conditions in any other agreement whether oral or written. This Agreement supersedes any prior written or oral agreements between the parties.

 

5.4            Amendment. This Agreement may be modified or amended if the amendment is made in writing and signed by both parties.

 

5.5            Severability. If any provision of this Agreement shall be held to be invalid or unenforceable for any reason, the remaining provisions shall continue to be valid and enforceable. If a court finds that any provision of this Agreement is invalid or unenforceable, but that by limiting such provision it would become valid and enforceable, then such provision shall be deemed to be written, construed, and enforced as so limited.

 

5.6            Governing Law; Exclusive Jurisdiction.

 

(i)             This Agreement and the relationship of the parties hereto shall be governed by and construed in accordance with the internal laws (and not the law of conflicts) of the State of Delaware.

 

(ii)             Each of the parties hereto agrees that any suit, action, or proceeding seeking to enforce any provision of, or based on any matter arising out of or in connection with, this Agreement shall be brought solely in any state or federal court sitting in the State of Delaware. Each of the parties hereto consents to the jurisdiction of such court (and of the appropriate appellate courts therefrom) in any such suit, action, or proceeding and irrevocably agrees not to commence any litigation relating thereto except in such court, and each further waives any objection to the laying of venue of any such litigation in such court and agrees not to plead or claim in such court that such litigation brought therein has been brought in an inconvenient forum. Any party hereto may make service on another party by sending or delivering a copy of the process to the party to be served at the address and in the manner provided for the giving of notices in Section 5.1. Nothing in this Section 5.6, however, shall affect the right of any Person to serve legal process in any other manner permitted by law.

 

4 

 

 

5.7            Counterparts. This Agreement may be executed in separate counterparts, either of which, when so executed, shall be deemed to be an original and both of which, when taken together, shall constitute but one and the same agreement.

 

5.8            Survival. The representations, warranties, covenants, and agreements made herein shall survive the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby, notwithstanding any investigation made by either party.

 

5.9            Further Assurances. Each party shall at any time and from time to time after the date hereof take whatever actions the other party or its affiliates or agents reasonably request to effectuate, record, evidence or perfect its transfer of the Shares to the Corporation pursuant to this Agreement or to otherwise effectuate or consummate any of the transactions contemplated hereby.

 

THERIVA BIOLOGICS, INC.   STOCKHOLDER:
     
     
By:                     
Name: Steven A. Shallcross      
Title: Chief Executive Officer and    
  Chief Financial Officer    

 

5 

 

 EX-101.SCH 3 syn-20221220.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 syn-20221220_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 syn-20221220_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Dec. 20, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 20, 2022
Entity File Number 001-12584
Entity Registrant Name THERIVA BIOLOGICS, INC.
Entity Central Index Key 0000894158
Entity Tax Identification Number 13-3808303
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 9605 Medical Center Drive
Entity Address, Address Line Two Suite 270
Entity Address, City or Town Rockville
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20850
City Area Code 301
Local Phone Number 417-4364
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol TOVX
Security Exchange Name NYSEAMER
Entity Emerging Growth Company false
XML 7 tm2233416d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000894158 2022-12-20 2022-12-20 iso4217:USD shares iso4217:USD shares 0000894158 false 8-K 2022-12-20 THERIVA BIOLOGICS, INC. NV 001-12584 13-3808303 9605 Medical Center Drive Suite 270 Rockville MD 20850 301 417-4364 false false false false Common stock, par value $0.001 per share TOVX NYSEAMER false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://syntheticbiologics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2233416d1_8k.htm syn-20221220.xsd syn-20221220_lab.xml syn-20221220_pre.xml tm2233416d1_ex10-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2233416d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2233416d1_8k.htm" ] }, "labelLink": { "local": [ "syn-20221220_lab.xml" ] }, "presentationLink": { "local": [ "syn-20221220_pre.xml" ] }, "schema": { "local": [ "syn-20221220.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "syn", "nsuri": "http://syntheticbiologics.com/20221220", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2233416d1_8k.htm", "contextRef": "From2022-12-20to2022-12-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://syntheticbiologics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2233416d1_8k.htm", "contextRef": "From2022-12-20to2022-12-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://syntheticbiologics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001104659-22-129900-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-129900-xbrl.zip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end